What question did this study set out to answer?

To explore the binding and intercalation of astatine-211 in zirconium phosphate nanoplatelets for alpha therapy.

April 26, 2026Small Science0 citationsOpen Access

Front Cover: Uptake and Binding of At‐211 Into K‐ and Cs‐Derivatives of Alpha‐Zirconium Phosphate Nanoplatelets for Use as a Targeted Alpha Therapy Delivery Platform (Small Sci. 4/2026)

BMB D Imansha Madhushan AOAdrianna L Orsi JPJehan S. Perera

Key Points

To explore the binding and intercalation of astatine-211 in zirconium phosphate nanoplatelets for alpha therapy.
Labelling alpha-zirconium phosphate nanoplatelets with astatine-211 isotope.
Assessing the uptake and binding of astatine-211 between nanoplatelet layers.
Astatine-211 successfully binds to zirconium phosphate nanoplatelets.
The platform effectively shields alpha radiation, protecting healthy tissue.

Abstract

Targeted Alpha Therapy Intercalation and binding of astatine-211 between the layers of alkaline-substituted alpha-zirconium phosphate nanoplatelets. Labelling these zirconium phosphate nanoplatelets with the alpha-emitting isotope astatine-211 is the first step towards providing a viable targeted alpha therapy (TAT) radiopharmaceutical. This platform also shields the emission of alpha radiation, limiting damage to healthy tissue during administration. More in article number e202500640, Jonathan D. Burns and co-workers.

Perguntar à IA

Bookmark

View Full Paper